Alvotech Kicks Off Trials For Eylea Biosimilar
AVT06 Proposed Version Of Aflibercept Enters Clinical Studies
Alvotech has announced the start of clinical trials for its AVT06 proposed aflibercept biosimilar rival to Eylea, joining a host of other developers pursuing the same target.
You may also be interested in...
Alvotech Links Up With Polifarma On Proposed Eylea Biosimilar
Alvotech has signed an agreement with Polifarma to distribute its proposed aflibercept biosimilar in Turkey. The compound, AVT06, is currently in the development stage.
Alvotech’s Simponi Rival Begins Pharmacokinetic Study
Alvotech’s Simponi rival enters Phase I trials after a dynamic year for the company’s development and commercialization program. Meanwhile, the biosimilars developer has also expanded its Japanese collaboration with Fuji Pharma.
Lupin And DKSH To Market Five Alvotech Biosimilars In The Philippines
Lupin’s Multicare Pharmaceuticals subsidiary in the Philippines will partner with distributor DKSH to market five Alvotech biosimilars. Alvotech’s biosimilars, which remain at the pre-approval stages, reference Prolia/Xgeva, Eylea, Simponi, and two more undisclosed molecules.